Viking Therapeutics
VKTX
Viking Therapeutics (VKTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.10
- EPS estimate
- −$1.11
- EPS surprise
- +0.72%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Jul 29, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | −$1.11 | −$1.10 | +0.72% | $0.00 | SEC |
| Q1 2026 | Apr 29, 2026 | −$0.98 | −$1.37 | −40.43% | $0.00 | SEC |
| Q4 2025 | Feb 11, 2026 | −$0.90 | −$1.38 | −53.81% | $0.00 | SEC |
| Q3 2025 | Oct 22, 2025 | −$0.71 | −$0.81 | −14.15% | $0.00 | SEC |
| Q2 2025 | Jul 23, 2025 | −$0.45 | −$0.58 | −29.90% | $0.00 | SEC |
| Q1 2025 | Apr 23, 2025 | −$0.33 | −$0.41 | −25.00% | $0.00 | SEC |
| Q4 2024 | Feb 5, 2025 | −$0.28 | −$0.32 | −15.98% | $0.00 | SEC |
| Q3 2024 | Oct 23, 2024 | −$0.24 | −$0.22 | +9.43% | $0.00 | SEC |
| Q2 2024 | Jul 24, 2024 | −$0.26 | −$0.20 | +23.84% | $0.00 | SEC |
| Q1 2024 | Apr 24, 2024 | −$0.28 | −$0.26 | +6.04% | $0.00 | SEC |
| Q4 2023 | Feb 7, 2024 | −$0.25 | −$0.25 | +1.57% | $0.00 | SEC |
| Q3 2023 | Oct 25, 2023 | −$0.22 | −$0.23 | −5.02% | $0.00 | SEC |
| Q2 2023 | Jul 26, 2023 | −$0.19 | −$0.19 | +1.40% | $0.00 | SEC |
| Q1 2023 | Apr 26, 2023 | −$0.24 | −$0.25 | −4.08% | $0.00 | SEC |
| Q4 2022 | Feb 8, 2023 | −$0.23 | −$0.26 | −11.92% | $0.00 | SEC |
| Q3 2022 | Oct 26, 2022 | −$0.23 | −$0.21 | +9.87% | $0.00 | SEC |
| Q2 2022 | Jul 27, 2022 | −$0.21 | −$0.23 | −8.49% | $0.00 | SEC |
| Q1 2022 | Apr 27, 2022 | −$0.19 | −$0.21 | −9.38% | $0.00 | SEC |
| Q4 2021 | Feb 9, 2022 | −$0.19 | −$0.16 | +14.44% | $0.00 | SEC |
| Q3 2021 | Nov 3, 2021 | −$0.21 | −$0.17 | +19.05% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Viking Therapeutics (VKTX) last report earnings?
Viking Therapeutics last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did VKTX beat earnings estimates?
Yes. Viking Therapeutics reported EPS of −$1.10 for Q2 2026 against a −$1.11 estimate — a 0.72% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.